NEWS: 公告在東京證券交易所JASDAQ標準市場新上市



Doxorubicin Market - Growth, Trends, and Forecasts (2020 - 2025)

出版商 Mordor Intelligence Pvt Ltd 商品編碼 708650
出版日期 內容資訊 英文 100 Pages
商品交期: 2-3個工作天內
阿霉素的全球市場:成長,趨勢,及預測 Doxorubicin Market - Growth, Trends, and Forecasts (2020 - 2025)
出版日期: 2020年06月01日內容資訊: 英文 100 Pages



第1章 簡介

  • 調查成果
  • 調查的假設
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 成長要素
  • 市場阻礙因素
  • 波特的五力分析
    • 新加入廠商的威脅
    • 買主/消費者談判力
    • 供應商談判力
    • 替代產品的威脅
    • 產業內的競爭

第5章 市場區隔

  • 藥物的各形狀
  • 各用途
    • 膀胱癌
    • 卡波西氏肉瘤
    • 白血病
    • 淋巴瘤
    • 乳癌
    • 其他
  • 各流通管道
    • 醫院藥局
    • 零售藥局
    • 線上藥局
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他

第6章 競爭情形

  • 企業簡介
    • Cadila Pharmaceuticals
    • Cipla Inc.
    • Johnson and Johnson
    • Pfizer Inc.
    • SRS Pharmaceuticals Pvt. Ltd
    • Sun Pharmaceutical Industries Ltd.

第7章 市場機會及未來趨勢


Product Code: 64363

The market for Doxorubicin is majorly driven by the rising cases of cancer across the globe. As per the statistics provided by the National Cancer Institute (NCI), 1,762,450 new cancer cases and 606,880 cancer deaths are estimated for the year 2019. During the year 2018, the new cancer cases were around 1,735,350. The incidence of cancer given by the NCI is around 439.2 per 100,000 individuals per year.

Along with that, the mortality due to cancer is also on the rise and it is around 196.8 per 100,000 men and 139.6 per 100,000 women. During the year 2017, 15,270 children and adolescents ages 0 to 19 were diagnosed with cancer and 1,790 were died due to the same.

However, in the year 2016, 15.5 million people have survived cancer in the United States, and this number is expected to reach up to 20.3 million by 2026. This indicates that due to the available treatment options, mortality due to the disease is being prevented and the same trend will be seen in the coming future.

Key Market Trends

Doxorubicin Market in Breast Cancer Segment is Expected to Witness Better CAGR Over the Forecast Period

Despite the fact that doxorubicin is used to treat several types of cancers, the most common cancer that can be treated with the same is breast cancer. Cancer has become the leading cause of death across the globe and there were around 9.6 million deaths in 2018. Globally, about 1 in 6 deaths is due to cancer, as stated by the World Health Organization (WHO).

According to WHO, the number of cases of Breast Cancer that were found in the year 2018 was around 2.09 million which is similar to that of lung cancer cases for that year. American Cancer Institute has stated that Doxorubicin is used during the advanced breast cancer treatment as a chemo drug. It is observed that currently, 3 million women diagnosed with breast cancer are there in the United States. Due to the rising burden of disease, a large number of people are going for the treatment which is ultimately helping the market studied to grow. Therefore, it is estimated that breast cancer segment will show rapid growth over the forecast period.

North America is Expected to Dominate the Market Over the Forecast Period

North America is expected to dominate the market throughout the forecast period. The growing number of cancer cases and subsequently increasing usage of the doxorubicin in mono and combination chemotherapies are going to impact the market. Moreover, the increasing number of mergers and acquisitions and partnerships for clinical trials with technologically advanced doxorubicin formulations is one of the crucial factors driving the market in this region.

Competitive Landscape

The market for Doxorubicin consists of the few players which are big pharmaceutical companies. Some of the major players of the market include Cadila Pharmaceuticals, Cipla, Limited, Pfizer, Inc., Johnson & Johnson (Janssen Pharmaceutical) among others. With the growing focus on cancer reduction across the globe, more pharmaceutical companies are expected to penetrate the market in the coming future.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents


  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Number of Companies Manufacturing Doxorubicin
    • 4.2.2 Rising Application of Doxorubicin in Cancer Treatment
    • 4.2.3 Increasing Prevalence of Cancer Across the Globe
  • 4.3 Market Restraints
    • 4.3.1 Side Effects Associated with Doxorubicin
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Drug Formulation
    • 5.1.1 Lyophilized Powder
    • 5.1.2 Doxorubicin Injection
  • 5.2 By Application
    • 5.2.1 Bladder Cancer
    • 5.2.2 Kaposi Sarcoma
    • 5.2.3 Leukemia
    • 5.2.4 Lymphoma
    • 5.2.5 Breast Cancer
    • 5.2.6 Others
  • 5.3 By Distribution Channel
    • 5.3.1 Hospital Pharmacy
    • 5.3.2 Retail Pharmacy
    • 5.3.3 Online Pharmacy
  • 5.4 Geography
    • 5.4.1 North America
      • United States
      • Canada
      • Mexico
    • 5.4.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.4.3 Asia Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.4.4 Rest of World


  • 6.1 Company Profiles
    • 6.1.1 Baxter International Inc.
    • 6.1.2 Cadila Pharmaceuticals
    • 6.1.3 Cipla Limited
    • 6.1.4 Johnson and Johnson (Janssen Pharmaceutical)
    • 6.1.5 Pfizer Inc.
    • 6.1.6 SRS Pharmaceuticals Pvt. Ltd
    • 6.1.7 Sun Pharmaceutical Industries Ltd.